DDX3 regulates DNA damage-induced apoptosis and p53 stabilization  by Sun, Mianen et al.
Biochimica et Biophysica Acta 1833 (2013) 1489–1497
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrDDX3 regulates DNA damage-induced apoptosis and p53 stabilizationMianen Sun a,⁎, Tong Zhou b, Eric Jonasch a, Richard S. Jope c,d
a Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA
b Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
c Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA
d Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA⁎ Corresponding author at: Department of Genitourinar
of Texas, M.D. Anderson Cancer Center, 2121W. Holcomb
TX, 77030, USA. Tel.: +1 713 677 7441.
E-mail address: msun4@mdanderson.org (M. Sun).
0167-4889/$ – see front matter © 2013 Elsevier B.V. All
http://dx.doi.org/10.1016/j.bbamcr.2013.02.026a b s t r a c ta r t i c l e i n f oArticle history:
Received 28 August 2012
Received in revised form 4 February 2013
Accepted 21 February 2013
Available online 5 March 2013
Keywords:
DDX3
p53
Apoptosis
DNA damage
CamptothecinThe DEAD box protein family member DDX3 was previously identiﬁed as an inhibitor of death receptor-
mediated extrinsic apoptotic signaling. However, there had been no studies of the role of DDX3 in regulating
the other major type of apoptosis, intrinsic apoptotic signaling, which was examined here. Intrinsic apoptosis
was induced in MCF-7 cells by treatment with staurosporine, a general kinase inhibitor, thapsigargin, which
induces endoplasmic reticulum (ER) stress, and camptothecin, which causes DNA damage. Each of these
treatments caused time-dependent activation of caspase-7, the predominant executioner caspase in these
cells. Depletion of DDX3 using shRNA did not alter apoptotic responses to staurosporine or thapsigargin.
However, caspase-7 activation induced by camptothecin was regulated by DDX3 in a manner dependent
on the functional status of p53. Depletion of DDX3 abrogated camptothecin-induced caspase-7 activation
in MCF-7 cells expressing functional wild-type p53, but oppositely potentiated camptothecin-mediated
caspase activation in cells expressing mutant or non-functional p53, which was accompanied by increased
activation of the extrinsic apoptotic signaling initiator caspase-8. In MCF-7 cells, depletion of DDX3 reduced
by more than 50% camptothecin-induced p53 accumulation, and this effect was blocked by inhibition of the
proteasome with MG132, indicating that DDX3 regulates p53 not at expression level but rather its stabiliza-
tion after DNA damage. Co-immunoprecipitation experiments demonstrated that DDX3 associates with p53,
and overexpression of DDX3 was sufﬁcient to double the accumulation of p53 in the nucleus after DNA
damage. Thus, DDX3 associates with p53, increases p53 accumulation, and positively regulates camptothecin-
induced apoptotic signaling in cells expressing functional wild-type p53, whereas in cells expressing mutant
or non-functional p53 DDX3 inhibits activation of the extrinsic apoptotic pathway to reduce caspase activation.
These results demonstrate that DDX3 not only regulates extrinsic apoptotic signaling, as previously reported, but
also selectively regulates intrinsic apoptotic signaling following DNA damage.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
DDX3 is a member of the DEAD box family of proteins, named for a
conserved D-E-A-D sequence, that contain putative ATPase and RNA
helicase domains [1–3]. There is limited knowledge about the func-
tions of DDX3, which were originally linked to actions of the hepatitis
C and human immunodeﬁciency viruses [4–6]. DDX3 is a nucleo-
cytoplasmic shuttling protein [5,7], associates with the Sp1 transcrip-
tion factor in the nucleus, and contributes to regulating cyclin D1,
cyclin E1, and p21 [8–11]. Recently, several ﬁndings linked DDX3 to
cancer. DDX3 levels were decreased in hepatocellular carcinomas
[8,9], although another study reported the opposite relationship
[12], DDX3 levels increased in carcinogen-treated MCF-7 cells [13],
DDX3 impedes death receptor-induced apoptosis [14,15], and DDX3y Medical Oncology, University
e Blvd, IBT Room 925, Houston,
rights reserved.regulates Snail and affects cancer cell motility and proliferation [16].
Theseﬁndings raised thepossibility thatDDX3mayhave regulatory inﬂu-
ences on the development, progression, or treatment of certain cancers.
Many cancers containmutated p53, a tumor suppressor transcription
factor that is activated by a wide variety of cellular stresses, notably DNA
damage [17–19]. p53 is a rapidly turning-over protein that is usually
maintained at low levels by rapid degradation through ubiquitin-
dependent proteolysis [20]. Post-translationmodiﬁcations, such as phos-
phorylation, and interactions with other proteins are important regula-
tors of the stabilization and activation of the normally short-lived p53
[21,22]. Activation leads to accumulation of p53 in the nucleus where it
regulates the expression of genes and ultimately leads to two
well-deﬁned cellular responses, cell cycle arrest and apoptosis.
Herein we report that DDX3 contributes to regulating apoptotic sig-
naling and the accumulation of p53 after DNA damage. DDX3 promotes
the retention and accumulation of p53 in the nucleus, which
co-immunoprecipitation experiments suggest may be mediated by
the association of DDX3 with p53. In cells expressing functional wild-
type p53, DDX3 positively regulates DNA damage-induced caspase
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Fig. 1. DDX3 protects MCF-7 cells from DNA damage-induced apoptosis but potentiates it
in HeLa cells.Wild-type (WT) and DDX3knockdown (KD) stableMCF-7 cellswere treated
for the indicated times with (A) 1 μM staurosporine, (B) 1 μM thapsigargin (after over-
night preincubation in serum free media), or (C) 10 μM camptothecin (after overnight
preincubation in serum freemedia). (D) HeLa cells and (E)MDA-MB-231 cells were treat-
ed with 10 μM camptothecin for the indicated time points (after overnight preincubation
in serum free media). Cell extracts were collected and immunoblotted for active
caspase-3/7, cleaved PARP, DDX3, and β-actin as a loading control. (F) MCF-7, (G) HeLa
and (H) MDA-MB231 wild-type (WT) and DDX3 knockdown (KD) cells were treated
with 10 μM Adriamycin for the indicated time points, followed by immunoblotting for
active caspase-3/7, cleaved-PARP, DDX3 and β-actin. Experiments were repeated at least
two times with similar results.
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DNA damage-induced caspase activation.
2. Results
2.1. Apoptosis induced by DNA damage is selectively affected by DDX3
SinceDDX3was recently found to be anti-apoptotic towards extrinsic
death receptor-induced apoptosis [15],we tested if DDX3 alsomodulates
intrinsic apoptosis. Three stimuli that activate intrinsic apoptotic signal-
ing by different mechanisms were examined: staurosporine, a kinase
inhibitor well-known to induce intrinsic apoptosis in essentially all
types of cells [23], thapsigargin, which inhibits the Ca++-ATPase in the
endoplasmic reticulum (ER) to cause ER stress-induced apoptosis [24],
and camptothecin, a topoisomerase 1 inhibitor that causes DNA damage
resulting in p53-mediated apoptosis [25]. Apoptotic signaling was
detected by measuring activation of effector caspase 3 or 7 and cleavage
of their substrate PARP, and regulation by DDX3 was examined by using
cells inwhich the level of DDX3was knocked downby shRNA. Treatment
with 1 μMstaurosporine caused time-dependent activation of caspase-7
and cleavage of PARP in MCF-7 cells, and these responses were not al-
tered in cells with the level of DDX3 knocked down (Fig. 1A). MCF-7
cells treatedwith 1 μMthapsigargin also displayed time-dependent acti-
vation of caspase-7 and concomitant PARP cleavage, and these responses
were not changed by knockdown of DDX3 (Fig. 1B). In contrast to the
other two insults, knocking down DDX3 resulted in reduced caspase-7
activation and PARP cleavage in MCF-7 cells after treatment with
10 μM camptothecin (Fig. 1C). These results indicate that DDX3 does
not universally affect intrinsic apoptotic signaling, as it does extrinsic
apoptotic signaling, but DDX3 selectively regulates intrinsic apoptotic
signaling induced by DNA damage.
2.2. DDX3 promotes camptothecin-induced apoptosis in cells expressing
functional wild-type p53 but impedes apoptosis in cells with
nonfunctional p53
To test if the modulatory effect of DDX3 involves p53, a critical
mediator of DNA damage-induced apoptotic signaling, apoptosis was
measured inHeLa cells, which containwild-typep53 that is functionally
disabled due to the presence of the human papillomavirus E6 protein
[23,24] compared with MCF-7 cells that express active wild-type p53.
Caspase-3 activation and PARP cleavage increased time-dependently
after treatment of HeLa cells with 10 μM camptothecin (Fig. 1D).
Surprisingly, these apoptotic signals were ampliﬁed in cells with
DDX3 knocked down, similar to previous reports that DDX3 inhibits
extrinsic apoptotic signaling [14,15]. In addition, we tested another
p53 mutant breast cancer cell line MDA-MB-231 that expresses
mutant p53. MDA-MB-231 displayed a response similar to HeLa cells,
as the knockdown of DDX3 facilitated apoptosis signaling indicated by
activation of caspase-3 and PARP cleavage induced by camptothecin
treatment (Fig. 1E), further demonstrating that DDX3 inhibits
DNA damage-induced apoptosis in cells with non-functional p53.
Adriamycin, a topoisomerase II inhibitor, was used as another DNA
damaging agent to further examine the effect of DDX3. MCF-7, HeLa
and MDA-MB-231 cells, with DDX3 or with DDX3 knocked down,
were treated with Adriamycin (10 μM) for 24 or 48 h. Apoptosis was
reduced by knocking down DDX3 in MCF-7 cells, but was increased in
HeLa and MDA-MB-231 cells (Fig. 1F–G). These results indicate that
selective regulation by DDX3 of DNA damage-induced caspase activa-
tion is dependent on the functional status of p53.
To further examine howDDX3 regulates camptothecin-induced apo-
ptosis differently in cells with functional wild-type and mutant p53, p38
activation was examined because the p38 and p53 signaling pathways
can mutually regulate each other in response to DNA damage [26] and
the p38 pathway has been reported to be involved in the extrinsic apo-
ptotic pathway where DDX3 is known to be regulatory [27]. Followingcamptothecin treatment, DDX3 knockdown attenuated the activation
of p38 in MCF-7 cells with active p53 (Fig. 2A), but enhanced p38 acti-
vation in HeLa cells with nonfunctional p53 (Fig. 2B), as determined by
immunoblotting the active phosphorylated level of p38.
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activation induced by stimulation of death receptors [15]. Since the
caspase-8-mediated extrinsic apoptotic pathway has been reported
to be activated following DNA damage [28–35], we tested if this
was modulated by DDX3. Caspase-8 was activated, and this was in-
creased by DDX3 depletion, following DNA damage in HeLa cells
(Fig. 2C), and type I BJAB cells that express mutant, nonfunctional
p53 (Fig. 2D). Although this is unlikely to be the sole action of
DDX3 since increased caspase-3 activation was detected earlier than
caspase-8 activation, these results are consistent with previous
reports that death receptors can be activated after DNA damage and
that knocking down DDX3 promotes death receptor-induced apopto-
tic signaling. Furthermore, cell survival was measured in MCF-7
(Fig. 2E), HeLa (Fig. 2F) and MDA-MB-231 cells (Fig. 2G). Knocking
down DDX3 increased cell survival in MCF-7 cells with functional
p53, but reduced cell survival in HeLa cells with nonfunctional p53
and in MDA-MB-231 cells with mutant p53.
2.3. DDX3 knockdown reduces p53 accumulation in MCF-7 cells expressing
functional wild-type p53
Since p53 is a centralmediator of cellular responses to DNA damage,
we tested if DDX3modulates the level of p53 in response to DNA dam-
age caused by treatment with camptothecin in MCF-7 cells expressingfunctional wild-type p53. The cellular level of p53 increased time-
dependently following camptothecin treatment, and this accumulation
of p53was diminished in cells with depleted DDX3 (Fig. 3A) to a similar
extent as caspase-7 activationwas reduced byDDX3 depletion (Fig. 1C).
In contrast, DDX3 knockdown did not change p53 levels in the presence
or absence of camptothecin in HeLa cells expressing nonfunctional p53
(Fig. 3B) and in MDA-MB-231 cells expressing mutant p53 (Fig. 3C).
These results indicate that DDX3 may promote camptothecin-induced
caspase activation by promoting the accumulation of functional p53.
Furthermore, comparison of basal and camptothecin-induced p53
levels in two lines of MCF-7 cells with different extents of DDX3 knock-
down induced with two different shRNA sequences showed that there
was a direct relationship between less DDX3 and lower levels of p53
(Fig. 3D), suggesting that DDX3 supports accumulation of functional
wild-type p53. Quantitation of p53 levels from three individual experi-
ments demonstrated that knocking down DDX3 resulted in a 52 ± 8%
decrease in basal p53 and a 66 ± 5% decrease in p53 after 4 h of
camptothecin treatment (Fig. 3E). This relationship was further
conﬁrmed by treating MCF-7 cells with etoposide, a topoisomerase II
inhibitor, which resulted in much less p53 accumulation in MCF-7
cells with DDX3 knocked down than in wild-type cells (Fig. 3F).
We examined the subcellular localization of p53 regulated by DDX3
inMCF-7 cells after DNA damage. Treatmentwith camptothecin caused
accumulation of p53 in both the cytosol and nucleus, but with DDX3
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Fig. 2. DDX3 regulates DNA damage-induced apoptosis in a manner dependent on the functional status of p53. p-p38, p38 and p-JNK levels were measured in wild-type (WT) and
DDX3 knockdown (KD) (A) MCF-7 cells and (B) HeLa cells following treatment with 10 μM camptothecin for the indicated time points. Intact procaspase-8 (55/53 kDa) and cleaved
43/41 kDa caspase-8 and β-actin levels were measured after HeLa (C) and BJAB (D) cells were treated with 10 μM camptothecin for the indicated time points. Experiments were
repeated at least two times with similar results. Cell survival was examined after treatment with 0, 0.1, 1, and 10 μM camptothecin for 24 h in (E) MCF-7 cells, (F) HeLa cells, and
(G) MDA-MB-231 cells with DDX3 (WT) and with DDX3 knocked down (KD). Means ± SEM; n = 3; *p b 0.05.
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(Fig. 4). These results indicate DDX3 is an important factor in the accu-
mulation of p53 after DNA damage, as little p53 can accumulate after
DNA damage in the absence of DDX3, raising the possibility that DDX3
may associate with p53.
2.4. DDX3 associates with p53
To further test if DDX3 promotes the stabilization of p53, and if
this occurs under non-apoptotic conditions, cells were treated
with the proteasome inhibitor MG132 to cause accumulation of p53.
MG132 treatment (10 μM; 5 h) increased p53 levels equivalently in
MCF-7 cells with or without knockdown of DDX3 (Fig. 5A), indicating
that depletion of DDX3 did not impair the accumulation of p53
stabilized by proteasome inhibition. Since DDX3 can bind glycogen
synthase kinase-3 (GSK3) [15] and GSK3 can bind and regulate p53
[36], we also tested if treatment with the GSK3 inhibitor lithium
altered the basal or MG132-stabilized levels of p53 with or without
DDX3 knockdown. However, lithium treatment did not alter the ef-
fects of MG132 or DDX3 knockdown on the level of p53 (Fig. 5A),
suggesting that the effect of DDX3 is independent of GSK3.
Co-immunoprecipitation experimentswere used to test if there is an
association between DDX3 and p53. p53was immunoprecipitated fromwild-type and DDX3 knockdownMCF-7 cells, with and without stabili-
zation of p53 with MG132 treatment (10 μM; 5 h). These measure-
ments showed that DDX3 co-immunoprecipitated with p53, and more
DDX3 co-immunoprecipitated with p53 in cells with increased p53
levels caused by MG132 treatment (Fig. 5B). We also tested if DDX3
associates with p53 following camptothecin-induced DNA damage.
After treatment of MCF-7 cells with camptothecin for 2, and 4 h, p53
accumulated and DDX3 co-immunoprecipitated with p53 (Fig. 5C).
These results suggest that DDX3 binding to p53 contributes to the
accumulation of p53. Although, DDX3 interacted with mutant p53 in
untreated MDA-MB-231 cells, the interaction was reduced by
camptothecin treatment (Fig. 5D). We hypothesize that DDX3 interacts
withmutant p53 in the nucleus in the absence of DNA damage, but dis-
sociation upon DNAdamage allows DDX3 to translocate to death recep-
tors where it attenuates caspase-8 activation and apoptotic signaling.
2.5. DDX3 promotes nuclear functional wild-type p53 accumulation and
activates its downstream target p21 expression in response to DNA damage
Conversely to knocking down DDX3, we tested if overexpression of
DDX3 using an adenovirus constructwas capable of increasing p53 levels.
For these experiments human neuroblastoma SH-SY5Y cells were used
because nearly 100% of cells are infected with adenoviruses. In SH-SY5Y
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Fig. 3. DDX3 regulates p53 levels. p53 and β-actin levels were measured in (A) MCF-7, (B) HeLa and (C) MDA-MB-231 cells after wild-type (WT) and DDX3 knockdown (KD) cells
were treated with 10 μM camptothecin for the indicated time points. (D) Cell lysates of two lines of MCF-7 cells with different extents of DDX3 knockdown using shRNA sequence
#1 or #4 were immunoblotted for p53 and DDX3 before and after treatment with 10 μM camptothecin for 4 h. (E) p53 quantitative values are from basal and 4 h
camptothecin-treated samples and are means ± SEM; n = 3; *p b 0.05 comparing wild-type and DDX3 knockdown cells. (F) p53, DDX3, and β-actin levels were measured in
MCF-7 wild-type and DDX3 knockdown cells after 24 h treatment with 200 μM topoisomerase II inhibitor etoposide.
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(10 μM; 4 h) increased cytosolic and nuclear levels of p53 (Fig. 6A).
Overexpression of DDX3 caused a 2-fold increase in nuclear p53 after
camptothecin treatment, but did not alter the cytosolic level of p53
(Fig. 6B). Thus, DDX3 appears to be a limiting factor in regulating the
extent of nuclear p53 accumulation after DNA damage. Furthermore,
p21 as a well-characterized downstream target of p53 transactivation
was examined in MCF-7 cells with depletion of DDX3 and in SH-SY5Y
with overexpression of DDX3. The level of p21was increased in response
to DNA damage as expected, and this was abrogated by DDX3 depletion
(Fig. 6C) and further increased by DDX3 overexpression (Fig. 6D).
3. Discussion
Recent reports have linked DDX3 to signaling events important in
carcinogenesis and chemotherapy, as discussed in the Introduction.Cytosolic
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functional p53. Second, DDX3 was found to have a regulatory effect
in controlling the extent of functional wild-type p53 accumulation
after DNA damage. These ﬁndings reveal that DDX3 has previously
unrecognized actions that regulate these key cellular responses to
DNA damage.
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ing pathways are not targets of DDX3 for its regulation of death
receptor-mediated apoptosis. This further supports the previously
reported conclusion that in the extrinsic apoptotic pathway, DDX3 in-
hibits caspase activation by an anti-apoptotic action as part of a protein
complex associated with death receptors [15]. Thus, the components of
apoptotic signaling that are common to both the extrinsic and intrinsic
apoptotic signaling pathways appear not to be inﬂuenced by DDX3.
In contrast to the ﬁnding that caspase activation induced by
staurosporine and thapsigargin was independent of DDX3, caspase-7
activation following DNA damage induced by camptothecin was clearly
impeded by DDX3 depletion in MCF-7 cells, an effect opposite to
the promotion of death receptor-induced apoptosis caused by DDX3
depletion. However, upon testing if this regulation of the response toDNA damage was an effect of DDX3 common to other cell types, we
encountered the paradoxical ﬁnding that camptothecin-induced
caspase-3 activation was enhanced by DDX3 depletion in both HeLa
and MDA-MB-231 cells. Thus, DDX3 depletion had opposite effects in
MCF-7 cells compared with HeLa and MDA-MB-231 cells on DNA
damage-induced executioner caspase-3/7 activation. This paradox ap-
pears to be due to the differences in p53 in the cells. Whereas MCF-7
cells express functional wild-type p53, which has a key role in the in-
duction of apoptosis following DNA damage, HeLa cells, MDA-MB-231
cells and BJAB cells contain nonfunctional p53, and only with functional
wild-type p53 did DDX3 depletion reduce caspase activation, whereas
with nonfunctional p53 DDX3 depletion increased caspase-3 activation
in response to DNA damage. The latter effect, increased caspase activa-
tion associated with DDX3 depletion, appears to be partially due to the
engagement of the extrinsic apoptotic pathway in these cells following
DNA damage, as activation of the extrinsic apoptotic signaling-
associated caspase-8 was also increased in cells with DDX3 depletion,
in accordance with the previous ﬁnding that DDX3 is inhibitory towards
extrinsic apoptotic signaling [15]. Thus, knocking down DDX3 level
in cells with mutant or non-functional p53 permits greater activation
of the extrinsic apoptosis pathway after DNA damage than otherwise
occurs.
Oppositely to results in cells with non-functional p53, in cells that
contain functional wild-type p53, DDX3 depletion impaired both
caspase activation and p53 accumulation. The mechanism for DDX3
promoting DNA damage-induced caspase activation in cells containing
functional wild-type p53 appeared to be due to DDX3 participating in
the regulation of the accumulation of p53 following DNA damage, as
knocking downDDX3 reduced p53 levels, and DDX3 overexpression in-
creased p53 levels following DNA damage. However, accumulation of
p53 following inhibition of the proteasome with MG132 was indepen-
dent of DDX3. Since DDX3 co-immunoprecipitated with p53, together
these ﬁndings suggest that DDX3 binding to p53 promotes the accumu-
lation of p53, but not the expression of p53 based on the unchanged p53
levels in MG132-treated cells with or without knockdown of DDX3. In
support of this, overexpression of DDX3 was capable of increasing p53
levels even after p53 was stabilized by signals emanating from the
DNA damage cascade. These ﬁndings add to recent reports indicating
that DEAD box proteins have a variety of actions related to cell survival
as well as to modulation of mRNA [8,9,15,37–39]. Furthermore, another
prominent DEAD box protein DDX5/p68 also has been shown to be
involved in regulating cell proliferation, apoptosis, and p53 [40–44].
Thus, the repertoire of actions of DEAD box proteins extends beyond
their classical actions of regulating mRNA to also include functions
important in regulating signaling events important in cell survival and
apoptosis.
In summary, the results reported here reveal that DDX3 regulates
apoptotic signaling after DNA damage and contributes to the stabili-
zation of functional wild-type p53. Since DDX3 associates with p53,
the stabilization and nuclear accumulation of p53 following DNA
damage, the effect of DDX3 is likely at least in part due to promoting
nuclear retention of p53. Overall, these results further demonstrate
that DDX3 plays important roles in regulating processes that are asso-
ciated with carcinogenesis and chemotherapy.4. Conclusion
This study found that DDX3 associates with p53, increases p53 ac-
cumulation, and positively regulates camptothecin-induced apoptotic
signaling in cells expressing functional wild-type p53, whereas in
cells expressing mutant p53 DDX3 inhibits activation of the extrinsic
apoptotic pathway to reduce caspase activation. These results
demonstrate that DDX3 not only regulates extrinsic apoptotic signal-
ing, as previously reported, but also selectively regulates intrinsic
apoptotic signaling following DNA damage.
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Fig. 6. DDX3 stabilizes nuclear p53 and increases p21 in response to DNA damage. (A) Cytosolic (left panels) and nuclear (right panels) fractions were prepared from SH-SY5Y
wild-type (WT) cells and SH-SY5Y cells after DDX3 overexpression (OE) by transient adenovirus infection with or without camptothecin (10 μM; 4 h) treatment, and
immunoblotted for p53 and DDX3. β-Tubulin and CREB were used as cytosol and nuclear loading controls, respectively. (B) p53 quantitative values are from basal and 4 h
camptothecin-treated cytosolic and nuclear samples in SH-SY5Y wild-type (WT) and DDX3 over-expressing (OE) cells. Means ± SEM; n = 3; *p b 0.05. (C) Wild-type and
DDX3 knockdown MCF-7 cells were treated with 10 μM camptothecin for 0, 2 and 3 h, followed by p21 and DDX3 level measurements. (D) Wild-type SH-SY5Y cells and
DDX3-overexpressing SH-SY5Y cells were treated with camptothecin for 0, 2 and 3 h, and protein levels of p21 and DDX3 were measured. Experiments were repeated three
times with similar results.
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5.1. Cell culture and materials
HeLa andMCF-7 cells were grown in Dulbecco's modiﬁed Eagle me-
dium (DMEM) supplemented with 10% fetal bovine serum (Invitrogen,
Carlsbad, CA), 100 U/ml penicillin, 100 μg/ml streptomycin, and 15 mM
HEPES, in humidiﬁed, 37 °C chambers with 5% CO2. BJAB cells were
grown in RPMI 1640 medium (Cellgro, Herndon, VA) supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, 10 mM HEPES, 1 mM
sodium-pyruvate, 2.5 g/l glucose, 100 U/ml penicillin and 100 μg/ml
streptomycin. Human neuroblastoma SH-SY5Y cells were grown in
50% Minimum Essential Medium Eagle (MEM) (Cellgro, Herndon, VA)
and 50% Kaighn's Modiﬁcation of Ham's F-12 (ATCC) supplementedwith 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml strep-
tomycin. Nuclei were extracted from cells with a nuclear extraction kit
according to the manufacturer's instructions (Active Motif). Sources of
chemicals were: lithium chloride, camptothecin (Sigma, St. Louis,
MO), thapsigargin, etoposide, staurosporine (Alexis Biochemicals, San
Diego, CA), and MG132 (Calbiochem, San Diego, CA). The following
sources provided antibodies: caspase-8, cleaved, active caspase-3/7,
cleaved 85 kDa fragment of poly(ADP-ribose) polymerase (PARP),
p38, p-p38 and p-JNK (Cell Signaling Technology, Beverly, MA),
β-actin (Sigma), and p53 (Transduction Laboratories, Lexington, KY).
DDX3 antibodies andDDX3 adenoviruswere prepared in the laboratory
of Dr. T. Zhou [12]. All horseradish peroxidase (HRP)-conjugated
secondary reagents were purchased from Southern Biotechnology
Associates (Birmingham, AL).
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Lentiviral mediated shRNA was performed using shRNA lentiviral
(pLKO.1-puro) plasmids (Sigma). The oligonucleotides containing
the DDX3 target sequence that were used are: sequence #1, 5′-CCG
GCCCTGCCAAACAAGCTAATATCTCGAGATATTAGCTTGTTTGGCAGGGT-
TTT and sequence #4, 5′-CCGGCGCTTGGAACAGGAACTCTTTCTCGAG
AAAGAGTTCCTGTTCCAAGCGTTTT.
One 100 mm dish of 293FT cells (Invitrogen) was co-transfected
with 3 μg of the pLKO.1-puro plasmids plus 3 μg each of the packaging
vectors pLP1, pLP2, and pLP/VSVG (Invitrogen) using Lipofectamine
2000. The media were changed approximately 16 h after transfection,
and the cells were cultured an additional 48–72 h. The media were
then collected, centrifuged at 3000 rpm for 5 min, and ﬁltered through
a 0.45 μm ﬁlter. Experimental cells were incubated with the virus-
containing medium overnight in 6-well plates, the media were
changed, and cells incubated for 24 h. Cells were transferred to
100 mm dishes and infected cells were selected by incubation in
puromycin (1 μg/ml). To overexpress DDX3, cells were infected with
adenovirus in serum-free media for 30 min, the media were changed
and cells grown for 48 h, followed by experiment assays.5.3. Immunoprecipitation and immunoblotting
After washing with PBS twice, cells were harvested in lysis buffer
(20 mM Tris, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM sodium
orthovanadate, 100 μM phenylmethylsulfonyl ﬂuoride, 10 μg/ml
leupeptin, 10 μg/ml aprotinin, 5 μg/ml pepstatin, 50 mM NaF, 1 nM
okadaic acid, 1% Triton X-100, and 10% glycerol) and centrifuged at
20,800 ×g for 15 min. For immunoprecipitation of p53, cell lysates
(500 μg protein) were incubated with anti-p53 antibody overnight,
followed by incubationwith protein G sepharose beads (GE Healthcare,
Piscataway, NJ) for 2 h. Beads were washed three times with 400 μl
lysis buffer, resuspended in 40 μl of Laemmli buffer, and the denatured
samples were run on 8–15% Tris/Glycine gels to detect the indicated
proteins.
For immunoblotting, cells werewashed twicewith PBS, and lysed in
lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM so-
dium orthovanadate, 100 μM phenylmethylsulfonyl ﬂuoride, 10 μg/ml
leupeptin, 10 μg/ml aprotinin, 5 μg/ml pepstatin, 50 mM NaF, 1 nM
okadaic acid, 1% Triton X-100, and 10% glycerol). The lysates were incu-
bated for 30 min on ice, centrifuged at 20,800 ×g for 15 min, and super-
natants were collected. Protein concentrations were determined using
the bicinchoninic method (Pierce, Rockford, IL). Cell lysates were
mixed with Laemmli sample buffer and placed in a boiling water bath
for 5 min. Proteins were resolved in SDS-polyacrylamide gels, and
transferred to nitrocellulose. Blots were probedwith the indicated anti-
bodies, and were developed using horseradish peroxidase-conjugated
goat anti-mouse or goat anti-rabbit IgG, followed by detection with
enhanced chemiluminescence.List of abbreviations
DDX3 DEAD box protein 3
ShRNA short hairpin RNA
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